Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Could Be Made To Pay For Stronger HTA Cooperation in EU

Executive Summary

The European Commission wants to strengthen EU cooperation in the area of health technology assessment. Among the options it is considering are mandatory and voluntary participation models… and charging drug companies fees.

You may also be interested in...

€20m Action Tackles Poor Uptake Of Joint HTAs Across Europe; Commission Consultation Nears

Europe’s EUnetHTA collaboration is working on producing a raft of new joint HTA reports for medical device and drug developers, and it is planning to facilitate 35 early dialogues between HTA bodies and manufacturers. It is also exploring why only a few European countries are making full use of the reports it has produced so far. Meanwhile, the European Commission is gearing up to consult extensively on how to create a sustainable network for HTAs across Europe.

As Appraisal Fees Loom, NICE Says No To Industry Calls For Reform

A proposal by the UK's HTA body NICE to charge companies for technology appraisals has raised several issues, such as the need for reforms to the HTA process, ensuring independence and credibility of appraisals, greater accountability and transparency at NICE, and the impact of fees on bringing new medicines to market.

European CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts